Atika Capital Management LLC Acquires New Holdings in Insmed, Inc. $INSM

Key Points

• Atika Capital Management LLC has acquired a new stake in Insmed, Inc., purchasing 96,000 shares valued at approximately $7.32 million, which represents about 0.05% ownership of the company.
• Insmed has received positive ratings from analysts, with multiple firms raising their price targets, including Goldman Sachs, which increased its target from $114 to $142, and Mizuho, which raised theirs from $130 to $165.
• Insmed reported a **missed earnings estimate** for the quarter, posting an EPS of ($1.70) against an expected ($1.30), despite a year-over-year revenue increase of 18.9% to $107.42 million.

Atika Capital Management LLC acquired a new stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 96,000 shares of the biopharmaceutical company's stock, valued at approximately $7,324,000. Atika Capital Management LLC owned approximately 0.05% of Insmed at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Insmed in the 1st quarter worth approximately $975,000. OneDigital Investment Advisors LLC lifted its position in shares of Insmed by 47.1% in the 1st quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company's stock worth $399,000 after purchasing an additional 1,673 shares during the period. Sowell Financial Services LLC purchased a new stake in shares of Insmed in the 1st quarter worth about $255,000. GAMMA Investing LLC lifted its position in shares of Insmed by 62.0% in the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock worth $77,000 after purchasing an additional 386 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of Insmed by 16.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 3,772 shares of the biopharmaceutical company's stock worth $288,000 after acquiring an additional 541 shares in the last quarter.

Wall Street Analysts Forecast Growth

INSM has been the subject of a number of analyst reports. The Goldman Sachs Group raised their price objective on shares of Insmed from $114.00 to $142.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. William Blair initiated coverage on shares of Insmed in a research note on Wednesday. They issued an "outperform" rating for the company. Truist Financial lifted their price target on shares of Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. Mizuho lifted their price target on shares of Insmed from $130.00 to $165.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 13th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a research note on Wednesday. Sixteen investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $131.29.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $129.45 on Thursday. The firm has a 50 day moving average of $106.10 and a 200 day moving average of $84.93. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $27.36 billion, a price-to-earnings ratio of -22.67 and a beta of 0.95. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $130.13.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The company had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.Insmed's quarterly revenue was up 18.9% compared to the same quarter last year. During the same period last year, the firm posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In other news, CFO Sara Bonstein sold 58,400 shares of the company's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the transaction, the chief financial officer directly owned 73,505 shares in the company, valued at approximately $7,546,758.35. This represents a 44.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the transaction, the insider owned 89,407 shares in the company, valued at approximately $8,352,401.94. The trade was a 52.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 504,694 shares of company stock worth $48,660,104. Insiders own 3.00% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.